Can Retatrutide Extend Eli Lilly and Co (LLY)’s Lead in Weight Loss Market?

Eli Lilly and Co (NYSE:LLY) is one of billionaire Ken Fisher’s top high growth stock picks. In the past month, Lilly shares have gained more than 18%. The shares have soared almost 50% over the past year.

A bottle with pills

On June 6, Eli Lilly and Co (NYSE:LLY) presented results from late-stage trials of its weight-loss drug candidate, retatrutide. In one trial, retatrutide was assessed in patients with obesity. In another trial, retatrutide was tested in patients with treatment-naive type 2 diabetes.

The results showed that participants taking the lower 4 mg ​dose of retatrutide achieved a roughly 19% weight loss. That was comparable to the highest dose of Zepbound, the company’s current blockbuster obesity therapy. Those taking the 12 mg dose shed around 70 pounds over an 80-week period. Moreover, one-third of those taking the 12 mg dose had their weight falling to a healthy range.

The results also showed that retatrutide was effective in relieving type 2 diabetes. Moreover, the drug’s tolerability was broadly in line with the current blockbuster. With its next-gen obesity drug candidate, retatrutide, Lilly looks to extend its lead in the lucrative weight-loss market.

Eli Lilly and Co (NYSE:LLY) is an American global pharmaceutical company based in Indiana. It develops, manufactures, and sells medicines for various diseases, including diabetes, obesity, cancer, and immunology. Lilly products are sold in more than 120 countries.

READ NEXT: 10 Best Hot Stocks to Buy for June and 8 Best Defensive Stocks to Buy Amid Geopolitical Tensions.

Disclosure: None. Follow Insider Monkey on Google News.